Related Experiment Video

Updated: May 2, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.1K

Papillary renal cell carcinoma: current progress and future directions

Przemyslaw W Twardowski1, Philip C Mack2, Primo N Lara2

  • 1Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA; Southwest Oncology Group, Portland, OR.

Clinical Genitourinary Cancer
|March 18, 2014
PubMed

Insights

Papillary renal cell carcinoma (pRCC), a kidney cancer subtype, is less responsive to current treatments. Research explores new therapeutic targets like MET and EGFR pathways for better patient outcomes.

Area of Science:

  • Oncology
  • Genitourinary Cancers

Background:

  • Papillary renal cell carcinoma (pRCC) is the second most common kidney cancer subtype.
  • pRCC has a distinct molecular profile compared to clear-cell carcinoma and lacks VHL gene mutations.
  • This cancer subtype shows limited response to contemporary kidney cancer therapies.

Purpose of the Study:

  • To outline the heredity and biology of the two main pRCC variants.
  • To discuss emerging therapeutic targets for pRCC treatment.
  • To review preclinical data and clinical trials for novel pRCC therapies.

Main Methods:

  • Review of scientific literature on pRCC heredity and biology.
  • Analysis of preclinical data on MET and EGFR pathway inhibition.
  • Summary of completed and ongoing clinical trials for pRCC.

Main Results:

  • pRCC exhibits unique genetic and molecular characteristics.
  • Inhibition of mesenchymal epithelial transition (MET) and epidermal growth factor receptor (EGFR) pathways are promising therapeutic strategies.
  • Combination therapy with MET and EGFR inhibitors shows potential based on preclinical data.

Conclusions:

  • Targeting MET and EGFR pathways offers new therapeutic avenues for pRCC.
  • Ongoing clinical trials are crucial for expanding treatment options for pRCC patients.
  • Further research into pRCC biology is essential for developing effective treatments.
Keywords:
ARQ197EGFR pathwayErlotinibMET pathwayTivantinib

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.0K
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K